Metabolomics Approaches in Bladder Cancer Diagnosis

Metabolomics has emerged as a pivotal discipline for the identification and quantification of small-molecule metabolites in biofluids, tissues and cellular systems, offering an unprecedented window into the biochemical alterations accompanying bladder cancer. By capturing the myriad of metabolic perturbations that arise in tumour initiation, progression and recurrence, metabolomics approaches promise to augment existing diagnostic modalities such as cystoscopy and cytology with minimally invasive tests. Urinary metabolomic profiling, in particular, exploits the direct contact between urine and the bladder epithelium, enabling the detection of disease-related metabolic signatures through non-targeted and targeted mass spectrometry or nuclear magnetic resonance (NMR) techniques. Advances in high-resolution instrumentation and multivariate statistical analysis have improved both the sensitivity and specificity of biomarker discovery, yielding panels of metabolites—ranging from amino acids and lipids to nucleosides—that discriminate malignant from benign states, stratify non-muscle invasive and muscle-invasive disease, and predict recurrence. Such developments hold global significance by facilitating early detection, guiding personalised therapy and reducing the burden of invasive surveillance.

Research from Nature Portfolio

Recent studies have harnessed ultra-high-resolution mass spectrometry and advanced chromatographic separation to analyse urinary metabolomes in large cohorts. In a 2023 investigation, an untargeted approach employing ultra-high-performance liquid chromatography coupled with ultra-high-resolution mass spectrometry profiled over 200 urine samples to distinguish bladder cancer patients from non-cancer controls. Multivariate and external validation analyses revealed distinct metabolic patterns correlating with tumour stage, grade and patient demographic factors, reinforcing the feasibility of a non-invasive diagnostic assay. An earlier clinical study applied liquid chromatography–mass spectrometry to monitor non-muscle invasive bladder cancer during post-treatment surveillance. Discriminant analysis of longitudinal urinary metabolic profiles identified perturbations in phenylalanine, arginine, proline and tryptophan pathways as candidate biomarkers, demonstrating high negative predictive value across risk strata and underscoring metabolomics as a tool for recurrence surveillance.

Metabolomics Approaches in Bladder Cancer Diagnosis publication trend

The graph below shows the total number of articles in metabolomics approaches in bladder cancer diagnosis across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomics: Comprehensive analysis of small molecules in biological systems.

Ultra-high-resolution mass spectrometry (UHRMS): Analytical technique that measures molecular masses with high precision.

Nuclear magnetic resonance (NMR) spectroscopy: Method for structural elucidation of metabolites based on nuclear spin properties.

Non-targeted metabolomics: Unbiased profiling approach aimed at detecting a broad spectrum of metabolites.

Orthogonal partial least squares discriminant analysis (OPLS-DA): Multivariate statistical tool for class separation and biomarker identification.

Biomarker: Measurable indicator of a biological or pathological state.

Cystoscopy: Endoscopic procedure used as a standard method to visualise the bladder interior.

References

1. Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer. Cancer Medicine (2017).
2. Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry. Scientific Reports (2023).
3. Bladder cancer recurrence surveillance by urine metabolomics analysis. Scientific Reports (2018).
4. Metabolic changes preceding bladder cancer occurrence among Korean men: a nested case-control study from the KCPS-II cohort. Cancer & Metabolism (2023).
5. Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review. International Journal of Molecular Sciences (2024).